Immunogenicity of SARS-CoV-2 messenger RNA Vaccines in Patients with Cancer

0
6
Using a prospective cohort, reseearchers assessed the seroconversion rates and anti-SARS-CoV-2 spike protein antibody titers following the 1st and 2nd dose of BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in patients with cancer in U.S. and Europe from January to April 2021.
[Cancer Cell]
Addeo, A., Shah, P. K., Bordry, N., Hudson, R. D., Albracht, B., Marco, M. D., Kaklamani, V., Dietrich, P.-Y., Taylor, B. S., Simand, P.-F., Patel, D., Wang, J., Labidi-galy, I., Fertani, S., Leach, R. J., Sandoval, J., Mesa, R., Lathrop, K., Mach, N., & Shah, D. P. (2021). Immunogenicity of SARS-CoV-2 messenger RNA Vaccines in Patients with Cancer. Cancer Cell, 0(0). https://doi.org/10.1016/j.ccell.2021.06.009 Cite
AbstractFull Article